13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001595725
Total reported value
$2.0B
$2.0B
93 檔
17.1%
As reported in its official Q2 2025 Form 13F filing, Rock Springs Capital Management LP's tracked investment portfolio stood at $2.0B with 93 total positions.
Rock Springs Capital Management LP executed strategic sector rebalancing during Q2 2025, establishing 9 new positions while fully exiting 12 holdings and trimming 29 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ARGX | Argenx Se - Adr | Stock-Healthcare | 6.04% | -1.85% | — | |
| 2 | LLY | Eli Lilly & Co | Stock-Healthcare | 5.66% | +0.43% | +2.64% | |
| 3 | ✓ | Merus N V | Stock-Other | 3.49% | — | +8.45% | |
| 4 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 3.39% | +0.21% | +3.23% | |
| 5 | INSM | Insmed Inc | Stock-Healthcare | 3.29% | -1.15% | +1.76% | |
| 6 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 3.15% | +0.08% | -0.24% | |
| 7 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 3.05% | +3.17% | +3.85% | |
| 8 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 2.78% | -0.75% | -19.61% | |
| 9 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 2.65% | -0.69% | -15.84% | |
| 10 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 2.59% | +0.14% | -14.03% | |
| 11 | BSX | Boston Scientific CORP | Stock-Healthcare | 2.38% | -0.81% | +28.16% | |
| 12 | ASND | Ascendis Pharma A/S | Stock-Other | 2.33% | -2.62% | EXIT | |
| 13 | IRTC | Irhythm Holdings Inc | Stock-Healthcare | 2.33% | -0.25% | -4.64% | |
| 14 | AKRO | Akero Therapeutics Inc | Stock-Other | 2.13% | — | -4.79% | |
| 15 | PEN | Penumbra Inc | Stock-Healthcare | 2.05% | -0.55% | -24.85% | |
| 16 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 2.05% | -0.63% | +189.25% | |
| 17 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 2.03% | -0.46% | -30.19% | |
| 18 | EVH | Evolent Health Inc - A | Stock-Other | 1.98% | +0.30% | +4.64% | |
| 19 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 1.90% | -0.14% | -3.67% | |
| 20 | EXK | Exact Sciences CORP | Stock-Materials | 1.89% | — | +19.17% | |
| 21 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 1.82% | -0.61% | — | |
| 22 | TVTX | Travere Therapeutics Inc | Stock-Other | 1.76% | +3.45% | -34.68% | |
| 23 | SRRK | Scholar Rock Holding CORP | Stock-Other | 1.75% | -0.22% | +4.28% | |
| 24 | DXCM | Dexcom Inc | Stock-Healthcare | 1.56% | -0.19% | -27.89% | |
| 25 | PHR | Phreesia Inc | Stock-Other | 1.48% | +0.05% | -27.09% | |
| 26 | 2655787D | Blueprint Medicines CORP | Stock-Other | 1.48% | — | -81.59% | |
| 27 | GPCR | Structure Therapeutics Inc | Stock-Other | 1.47% | -0.14% | +0.26% | |
| 28 | THC | Tenet Healthcare CORP | Stock-Healthcare | 1.43% | -0.25% | — | |
| 29 | CAI | Caris Life Sciences Inc | Stock-Other | 1.32% | -0.17% | — | |
| 30 | KYMR | Kymera Therapeutics Inc | Stock-Other | 1.22% | +0.10% | -43.31% | |
| 31 | OMDA | Omada Health Inc | Stock-Other | 1.05% | — | — | |
| 32 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.03% | +0.05% | — | |
| 33 | AZTA | Azenta Inc | Stock-Other | 1.02% | -0.21% | +11.66% | |
| 34 | ACHC | Acadia Healthcare Co Inc | Stock-Other | 0.98% | -0.10% | EXIT | |
| 35 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 0.98% | +0.44% | -49.75% | |
| 36 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 0.94% | -0.08% | +5.47% | |
| 37 | SMMT | Summit Therapeutics Inc | Stock-Other | 0.94% | -0.28% | -28.64% | |
| 38 | AGL | agilon health, inc. | Stock-Other | 0.94% | — | -5.75% | |
| 39 | OSCR | Oscar Health Inc - Class A | Stock-Healthcare | 0.94% | — | -33.33% | |
| 40 | VERA | Vera Therapeutics Inc | Stock-Other | 0.91% | -0.29% | +18.55% | |
| 41 | ELVN | Enliven Therapeutics Inc | Stock-Other | 0.88% | -0.76% | +50.56% | |
| 42 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 0.87% | +0.13% | +8.31% | |
| 43 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.81% | -0.51% | EXIT | |
| 44 | CMPX | Compass Therapeutics Inc | Stock-Other | 0.80% | -0.65% | — | |
| 45 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 0.78% | -0.23% | EXIT | |
| 46 | ACLXGBX | Arcellx Inc | Stock-Other | 0.76% | -1.15% | EXIT | |
| 47 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.75% | — | -33.20% | |
| 48 | DHR | Danaher CORP | Stock-Healthcare | 0.73% | +0.02% | +0.34% | |
| 49 | AM6 | Amicus Therapeutics Inc | Stock-Other | 0.70% | -0.02% | EXIT | |
| 50 | WST | West Pharmaceutical Services | Stock-Healthcare | 0.70% | — | -15.30% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | AGIO | Agios Pharmaceuticals Inc | +1.5% | +189.25% | Add |
| 2 | CAI | Caris Life Sciences Inc | +1.3% | NEW | New buy |
| 3 | ✓ | Merus N V | +1.1% | +8.45% | Add |
| 4 | OMDA | Omada Health Inc | +1.1% | NEW | New buy |
| 5 | INSM | Insmed Inc | +1% | +1.76% | Add |
| 6 | RYTM | Rhythm Pharmaceuticals Inc | +0.9% | +3.23% | Add |
| 7 | IRTC | Irhythm Holdings Inc | +0.8% | -4.64% | Trim |
| 8 | XBI | Ss Spdr S&p Biotech ETF | +0.8% | NEW | New buy |
| 9 | BSX | Boston Scientific CORP | +0.8% | +28.16% | Add |
| 10 | ACLXGBX | Arcellx Inc | +0.8% | NEW | New buy |
| 11 | EXK | Exact Sciences CORP | +0.7% | +19.17% | Add |
| 12 | AKRO | Akero Therapeutics Inc | +0.6% | -4.79% | Trim |
| 13 | EVH | Evolent Health Inc - A | +0.5% | +4.64% | Add |
| 14 | RVMD | Revolution Medicines Inc | +0.5% | +3.85% | Add |
| 15 | THC | Tenet Healthcare CORP | +0.4% | — | Unchanged |
| 16 | CDTX | Cidara Therapeutics Inc | +0.4% | NEW | New buy |
| 17 | ASND | Ascendis Pharma A/S | +0.4% | +0.46% | Add |
| 18 | COGT | Cogent Biosciences Inc | +0.4% | NEW | New buy |
| 19 | ELVN | Enliven Therapeutics Inc | +0.4% | +50.56% | Add |
| 20 | GPCR | Structure Therapeutics Inc | +0.4% | +0.26% | Add |
| 21 | SRRK | Scholar Rock Holding CORP | +0.4% | +4.28% | Add |
| 22 | SLNOEUR | Soleno Therapeutics Inc | +0.3% | +24.52% | Add |
| 23 | LLY | Eli Lilly & Co | +0.3% | +2.64% | Add |
| 24 | REGN | Regeneron Pharmaceuticals | +0.3% | +303.57% | Add |
| 25 | CMPX | Compass Therapeutics Inc | +0.3% | — | Unchanged |
| 26 | RARE | Ultragenyx Pharmaceutical In | +0.3% | -0.24% | Trim |
| 27 | TMO | Thermo Fisher Scientific Inc | +0.3% | NEW | New buy |
| 28 | VERA | Vera Therapeutics Inc | +0.2% | +18.55% | Add |
| 29 | CLDX | Celldex Therapeutics Inc | +0.2% | — | Unchanged |
| 30 | OSCR | Oscar Health Inc - Class A | +0.2% | -33.33% | Trim |
| 31 | MIRM | Mirum Pharmaceuticals Inc | +0.1% | -14.03% | Trim |
| 32 | AMLX | Amylyx Pharmaceuticals Inc | +0.1% | +45.61% | Add |
| 33 | PHVS | Pharvaris N.V. | +0.1% | — | Unchanged |
| 34 | ARDX | Ardelyx Inc | +0.1% | +42.45% | Add |
| 35 | ARGX | Argenx Se - Adr | +0.1% | — | Unchanged |
| 36 | AZTA | Azenta Inc | +0.1% | +11.66% | Add |
| 37 | JSPR | Jasper Therapeutics Inc | +0.1% | — | Unchanged |
| 38 | SION | Sionna Therapeutics Inc | +0.1% | — | Unchanged |
| 39 | CATX | Perspective Therapeutics Inc | +0.1% | — | Unchanged |
| 40 | GOSS | Gossamer Bio Inc | 0% | — | Unchanged |
| 41 | DHR | Danaher CORP | 0% | +0.34% | Add |
| 42 | ZLAB | Zai Lab Ltd-adr | 0% | -3.67% | Trim |
| 43 | XENE | Xenon Pharmaceuticals Inc | 0% | — | Unchanged |
| 44 | CRL | Charles River Laboratories | 0% | NEW | New buy |
| 45 | NGNE | Neurogene Inc | 0% | — | Unchanged |
| 46 | LENZ | Lenz Therapeutics Inc | 0% | +1.08% | Add |
| 47 | ✓ | Compugen LTD | 0% | — | Unchanged |
| 48 | CGEM | Cullinan Therapeutics Inc | 0% | +3.66% | Add |
| 49 | DYN | Dyne Therapeutics Inc | 0% | +10.77% | Add |
| 50 | PCVX | Vaxcyte Inc | 0% | NEW | New buy |
According to official SEC Form 13F filings, Rock Springs Capital Management LP reported a total U.S. public equity portfolio value of $2.0B across 93 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ARGX, LLY, MERUS N V) accounted for 17.1% of total reported equity market value during Q2 2025.
Top New Position Initiated
CAI
市值: $21.2M
Top Position Liquidated / Trimmed
LEGN
前期市值: $17.4M
During Q2 2025, Rock Springs Capital Management LP's top holdings by market value included ARGX (6.0%)、LLY (5.7%)、MERUS N V (3.5%). The largest single position, ARGX, represented 6.0% of total portfolio value.
In Q2 2025, Rock Springs Capital Management LP made 82 total portfolio adjustments, initiating 9 new buys, adding to 32 positions, trimming 29 holdings, and fully liquidating 12 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.